What is the recommended treatment regimen for nonspecific interstitial pneumonia (NSIP)?

Treatment of Nonspecific Interstitial Pneumonia (NSIP)

For idiopathic NSIP, initiate treatment with systemic corticosteroids alone or in combination with immunosuppressive agents (mycophenolate, azathioprine, or cyclophosphamide), with the specific regimen determined by the degree of inflammation versus fibrosis on imaging and pathology 1, 2.

First-Line Treatment Strategy

The treatment approach hinges on distinguishing between inflammatory-predominant and fibrotic-predominant disease:

Inflammatory-Predominant NSIP

• Preferred regimen: Corticosteroids (prednisone or equivalent) as monotherapy or combined with immunosuppressants
• Best responders: Patients with prominent lymphocytic inflammation on BAL (>15% lymphocytes), mixed NSIP/organizing pneumonia pattern on HRCT, and ground-glass opacities 3, 4
• Combination therapy: Corticosteroids plus azathioprine shows superior outcomes in preventing disease progression and relapse (adjusted HR 0.556) 4
• Alternative immunosuppressants include mycophenolate mofetil, cyclophosphamide, or cyclosporine 2

Fibrotic-Predominant NSIP

• Key imaging features: Prominent reticular changes, traction bronchiectasis, minimal ground-glass opacity 3
• Treatment response: Less responsive to immunosuppression alone 3
• Consider antifibrotic agents (nintedanib or pirfenidone) if disease progresses despite immunosuppression, particularly when meeting criteria for progressive pulmonary fibrosis (PPF) 1

Critical Decision Points

Baseline assessment determines treatment intensity:

• DLco <60% predicts higher risk of progression (adjusted HR 1.739) and warrants more aggressive combination therapy 4
• BAL lymphocytosis >15% predicts better response to immunosuppression (adjusted HR 0.592 for progression) 4
• Mild disease (FVC ≥70%, <20% fibrosis on HRCT) may be monitored initially with PFTs every 6 months 5

Second-Line Options for Progressive Disease

If disease progresses despite first-line immunosuppression:

1. Rituximab plus mycophenolate: Currently being evaluated in the EVER-ILD trial for NSIP non-responding to first-line therapy 6
2. Antifibrotic therapy: For fibrotic, progressive, immunosuppression-refractory NSIP, though evidence remains limited 3
3. Lung transplantation: For severe, progressive, refractory disease 3

Important Caveats

Exclude secondary causes before diagnosing idiopathic NSIP: Thoroughly evaluate for connective tissue disease (especially in middle-aged non-smoking women), drug toxicity, and hypersensitivity pneumonitis 7. If CTD-associated, follow the 2023 ACR/CHEST guidelines which conditionally recommend mycophenolate as preferred first-line therapy over other immunosuppressants 8.

Monitoring strategy:

• Short-term reassessment (PFTs within 3 months, HRCT within 6 months) to determine progression rate 5
• Moderate-to-severe disease requires PFTs every 3-6 months 5

Prognosis: Generally favorable with 5-year survival >70% and 10-year survival ~90%, significantly better than IPF 1, 2, 4. However, disease progression/relapse occurs in approximately 49% of patients and is the primary risk factor for mortality (adjusted HR 7.135) 4.

Supportive Care

Regardless of pharmacologic approach, implement:

• Oxygen therapy for hypoxemia
• Pulmonary rehabilitation
• Pneumocystis jirovecii pneumonia (PJP) prophylaxis with trimethoprim-sulfamethoxazole during immunosuppression
• Appropriate vaccinations (influenza, pneumococcus, COVID-19, RSV) 8